Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e319-

  Shemesh, Colby S ^a   Yu, Rosie Z ^a   Gaus, Hans J ^a   Greenlee, Sarah ^a   Post, Noah ^a   Schmidt, Karsten ^a   Migawa, Michael T ^a   Seth, Punit P ^a   Zanardi, Thomas A ^a   Prakash, Thazha P ^a   Swayze, Eric E ^a   Henry, Scott P ^a   Wang, Yanfeng ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense oligonucleotide; biotransformation; metabolism; N acetyl galactosamine; targeted drug delivery

Indexed keywords

ALCOHOL; ALDEHYDE DEHYDROGENASE; ALKALINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBONUCLEASE II; ION 681257; N ACETYL BETA GLUCOSAMINIDASE; N ACETYLGALACTOSAMINE; TRIANTENNARY N ACETYL GALACTOSAMINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONJUGATION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG ELIMINATION; FECES; LIVER; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; RADIOMETRY; RAT; URINE; ENZYME ACTIVITY; HAPLORHINI; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; METABOLISM; METABOLITE; RADIOACTIVITY;

EID: 85015179223     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.31     Document Type: Article

References (31)

1. 1 Crooke, ST, Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489 (1999), 31–44.
2. 2 Bennett, CF, Swayze, EE, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50 (2010), 259–293.
3. 3 Kanasty, R, Dorkin, JR, Vegas, A, Anderson, D, Delivery materials for siRNA therapeutics. Nat Mater 12 (2013), 967–977.
4. 4 Ming, X, Laing, B, Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev 87 (2015), 81–89.
5. 5 Prakash, TP, Graham, MJ, Yu, J, Carty, R, Low, A, Chappell, A, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42 (2014), 8796–8807.
6. 6 Khorev, O, Stokmaier, D, Schwardt, O, Cutting, B, Ernst, B, Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem 16 (2008), 5216–5231.
7. 7 Li, Y, Huang, G, Diakur, J, Wiebe, LI, Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 5 (2008), 299–302.
8. 8 Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18 (2010), 1357–1364.
9. 9 Geary, RS, Matson, J, Levin, AA, A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem 274 (1999), 241–248.
10. 10 Robison, TW, Jacobs, A, Metabolites in safety testing. Bioanalysis 1 (2009), 1193–1200.
11. 11 Walker, D, Brady, J, Dalvie, D, Davis, J, Dowty, M, Duncan, JN, et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22 (2009), 1653–1662.
12. 12 Baranczewski, P, Stańczak, A, Kautiainen, A, Sandin, P, Edlund, PO, Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep 58 (2006), 341–352.
13. 13 Baillie, TA, Cayen, MN, Fouda, H, Gerson, RJ, Green, JD, Grossman, SJ, et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol 182 (2002), 188–196.
14. 14 Wilkinson, GR, Drug metabolism and variability among patients in drug response. N Engl J Med 352 (2005), 2211–2221.
15. 15 Penner, N, Xu, L, Prakash, C, Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?. Chem Res Toxicol 25 (2012), 513–531.
16. 16 White, RE, Evans, DC, Hop, CE, Moore, DJ, Prakash, C, Surapaneni, S, et al. Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary. Xenobiotica, 43, 2013, 219 25; discussion 226.
17. 17 Gaus, HJ, Owens, SR, Winniman, M, Cooper, S, Cummins, LL, On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 69 (1997), 313–319.
18. 18 Graham, MJ, Crooke, ST, Monteith, DK, Cooper, SR, Lemonidis, KM, Stecker, KK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286 (1998), 447–458.
19. 19 Crooke, RM, Graham, MJ, Martin, MJ, Lemonidis, KM, Wyrzykiewiecz, T, Cummins, LL, Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther 292 (2000), 140–149.
20. 20 Baek, MS, Yu, RZ, Gaus, H, Grundy, JS, Geary, RS, In vitro metabolic stabilities and metabolism of 2′-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides 20 (2010), 309–316.
21. 21 Phillips, JA, Craig, SJ, Bayley, D, Christian, RA, Geary, R, Nicklin, PL, Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54 (1997), 657–668.
22. 22 Zhang, D, Luo, G, Ding, X, Lu, C, Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B 2 (2012), 549–561.
23. 23 Yu, RZ, Kim, TW, Hong, A, Watanabe, TA, Gaus, HJ, Geary, RS, Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35 (2007), 460–468.
24. 24 Yu, RZ, Lemonidis, KM, Graham, MJ, Matson, JE, Crooke, RM, Tribble, DL, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77 (2009), 910–919.
25. 25 FDA, Guidance for Industry: Safety Testing of Drug Metabolites. http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf, 2008.
26. 26 EMA, ICH Guideline M3(R2) on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.London, 2009.
27. 27 Prakash, TP, Yu, J, Migawa, MT, Kinberger, GA, Wan, WB, Østergaard, ME, et al. Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem 59 (2016), 2718–2733.
28. 28 Palme, R, Touma, C, Arias, N, Dominchin, MF, Lepschy, M, Steroid extraction: get the best out of faecal samples. Wiener Tierärzliche Monatsschrift 100 (2013), 238–246.
29. 29 Levsen, K, Schiebel, HM, Behnke, B, Dötzer, R, Dreher, W, Elend, M, et al. Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. J Chromatogr A 1067 (2005), 55–72.
30. 30 Kind, T, Fiehn, O, Seven golden rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. BMC Bioinformatics, 8, 2007, 105.
31. 31 Zhu, M, Zhang, H, Humphreys, WG, Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem 286 (2011), 25419–25425.